Flag of the European Union EU Clinical Trials Register Help

Clinical trials for nasopharyngeal cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44132   clinical trials with a EudraCT protocol, of which   7324   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: nasopharyngeal cancer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-001211-33 Sponsor Protocol Number: EFC10339 Start Date*: 2007-06-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyng...
    Medical condition: Children and adolescents newly diagnosed with NPC with measurable disease T2-T4 any NM, of <18 years of age at the time of diagnosis. ---------- Niños y adolescentes recien diagnosticados con CNF c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended) FR (Completed) IT (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001745-25 Sponsor Protocol Number: CC-486-NPC-001 Start Date*: 2015-01-22
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastati...
    Medical condition: Locally advanced or metastatic nasopharyngeal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005017-31 Sponsor Protocol Number: DERN Start Date*: 2019-01-29
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY
    Medical condition: advanced or metastatic Nose Pharynx Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004649-35 Sponsor Protocol Number: POINT Start Date*: 2021-12-14
    Sponsor Name:Fondazione GONO
    Full Title: Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer
    Medical condition: Nasopharyngeal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000230-29 Sponsor Protocol Number: CA209-358 Start Date*: 2015-09-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors
    Medical condition: Virus-associated tumors
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046885 Vaginal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061306 Nasopharyngeal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047777 Vulvar cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001530-14 Sponsor Protocol Number: NPC 2006 Start Date*: 2007-10-12
    Sponsor Name:GORTEC [...]
    1. GORTEC
    2.
    Full Title: Essai de Phase III, Multicentrique, Randomisé, comparant la Chimiothérapie d’induction par Docétaxel, Cisplatine et 5-Fluorouracile (TPF) suivie d’une chimio-radiothérapie concomitante versus une c...
    Medical condition: Patients atteints de cancers du nasopharynx classés T2b; T3;T4 ; OMS II-III et /ou avec envahissement ganglionnaire (Nsupérieur ou égal à 1)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026161 Malignant neoplasm of nasopharynx LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004939-22 Sponsor Protocol Number: HE 5/06 Start Date*: 2006-05-02
    Sponsor Name:Hellenic Cooperative Oncology Group (HeCOG)
    Full Title: A PHASE I/II EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH RECURRENT OR METASTATIC NON-NASOPHARYNGEAL HEAD AND NECK CANCER
    Medical condition: Recurrent or metastatic non-nasopharyngeal head and neck cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012225-12 Sponsor Protocol Number: 64-Cu-ATSM-CC-02/2009 Start Date*: 2009-09-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in head and neck cancer
    Medical condition: head and neck cancer. MEDRA code has not been found.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026184 LLT
    9.1 10026161 LLT
    9.1 10025963 LLT
    9.1 10025923 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000454-38 Sponsor Protocol Number: CPDR001X2201 Start Date*: 2015-10-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progr...
    Medical condition: Moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002360-14 Sponsor Protocol Number: AK-2016-HHC1 Start Date*: 2016-09-29
    Sponsor Name:Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET
    Full Title: Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer
    Medical condition: Oral squamous cell cancer (OSCC) with and with out local metastasis Oropharyngeal squamous cell cancer (OPSCC) with and with out local metastasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073040 Metastatic oropharyngeal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030961 Oral cancer stage unspecified LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028801 Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002259-39 Sponsor Protocol Number: TL-895-202 Start Date*: 2020-09-23
    Sponsor Name:Telios Pharma, Inc.
    Full Title: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients with cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001437-40 Sponsor Protocol Number: KO-TIP-007 Start Date*: 2019-03-08
    Sponsor Name:Kura Oncology, Inc.
    Full Title: The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM...
    Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) NO (Completed) BE (Completed) AT (Completed) NL (Completed) GR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002082-65 Sponsor Protocol Number: 2016-002082-65 Start Date*: 2016-10-26
    Sponsor Name:Andreas Kjaer
    Full Title: Phase II trial: uPAR-PET/CT for prognostication in head- and neck cancer
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004856 10026660 Malignant oral cavity neoplasms HLT
    19.0 100000004864 10028801 Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified HLT
    19.0 100000004864 10023826 Laryngeal neoplasms malignant HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001823-15 Sponsor Protocol Number: 20CH089 Start Date*: 2020-04-28
    Sponsor Name:CHU de Saint Etienne
    Full Title: Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study
    Medical condition: covid-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10070267 SARS virus test positive LLT
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002841-17 Sponsor Protocol Number: ASST-FARM_ONCO_TEPMEETCET-2022 Start Date*: 2023-04-07
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in patients with platinum-resistant head and neck squamous cel...
    Medical condition: in patients with platinum-resistant head and neck squamous cell carcinoma after relapse to immunotherapy “
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004318-16 Sponsor Protocol Number: DAS181-3-01 Start Date*: 2020-01-16
    Sponsor Name:Ansun Biopharma, Inc.
    Full Title: A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Medical condition: Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033796 Parainfluenzae viral infections HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002206-52 Sponsor Protocol Number: CD-ON-MEDI4736-1108 Start Date*: 2012-12-05
    Sponsor Name:MedImmune
    Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001188-96 Sponsor Protocol Number: 20PH061 Start Date*: 2020-04-07
    Sponsor Name:CHU de Saint Etienne
    Full Title: Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial
    Medical condition: Healthcare workers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10008434 Chemoprophylaxis NOS LLT
    20.0 100000004862 10061986 SARS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001523-69 Sponsor Protocol Number: V-CHANCE Start Date*: 2014-07-28
    Sponsor Name: Istituto Nazionale Tumori di Napoli - Fondazione "G. Pascale"
    Full Title: Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck
    Medical condition: Recurrent and/or metastatic squamous cell carcinoma of head and neck
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-004188-25 Sponsor Protocol Number: ASST_FARM_ONCO_P-ACC_2022 Start Date*: 2023-03-03
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: P-ACC Trial - Phase II, single arm, multicenter, open-label study of PARP inhibitors + cisplatin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
    Medical condition: patients with recurrent and/or Metastatic Adenoid Cystic Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073370 Adenoid cystic carcinoma of salivary gland PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085951 Adenoid cystic carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA